HUE061898T2 - Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok - Google Patents
Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorokInfo
- Publication number
- HUE061898T2 HUE061898T2 HUE18853233A HUE18853233A HUE061898T2 HU E061898 T2 HUE061898 T2 HU E061898T2 HU E18853233 A HUE18853233 A HU E18853233A HU E18853233 A HUE18853233 A HU E18853233A HU E061898 T2 HUE061898 T2 HU E061898T2
- Authority
- HU
- Hungary
- Prior art keywords
- imidazo
- pyrazine derivatives
- pi3kdelta
- inhibitors
- pi3kdelta inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2017101058 | 2017-09-08 | ||
| CN2017119373 | 2017-12-28 | ||
| CN2018086555 | 2018-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE061898T2 true HUE061898T2 (hu) | 2023-08-28 |
Family
ID=65633578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE18853233A HUE061898T2 (hu) | 2017-09-08 | 2018-09-07 | Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11220506B2 (ko) |
| EP (2) | EP3679042B1 (ko) |
| JP (1) | JP7128264B2 (ko) |
| KR (1) | KR20200052297A (ko) |
| CN (2) | CN111704615B (ko) |
| AU (2) | AU2018328569B2 (ko) |
| BR (1) | BR112020004500A2 (ko) |
| CA (1) | CA3072842A1 (ko) |
| DK (1) | DK3679042T3 (ko) |
| ES (1) | ES2944658T3 (ko) |
| FI (1) | FI3679042T3 (ko) |
| HU (1) | HUE061898T2 (ko) |
| IL (1) | IL272988B (ko) |
| MX (1) | MX2020002630A (ko) |
| NZ (1) | NZ761680A (ko) |
| PL (1) | PL3679042T3 (ko) |
| PT (1) | PT3679042T (ko) |
| SG (1) | SG11202001286SA (ko) |
| TW (2) | TW202336010A (ko) |
| WO (1) | WO2019047915A1 (ko) |
| ZA (1) | ZA202000875B (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11136323B2 (en) | 2016-12-07 | 2021-10-05 | Beigene, Ltd. | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors |
| JP7128264B2 (ja) | 2017-09-08 | 2022-08-30 | ベイジーン リミテッド | ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体 |
| TW202313617A (zh) * | 2021-05-27 | 2023-04-01 | 英屬開曼群島商百濟神州有限公司 | ＰＩ３Ｋδ抑制劑的鹽、其晶型、製備方法及用途 |
| WO2023040810A1 (en) * | 2021-09-14 | 2023-03-23 | Beigene, Ltd. | Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005089352A (ja) * | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| JP4916883B2 (ja) | 2003-10-15 | 2012-04-18 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | イミダゾピラジンチロシンキナーゼ阻害剤 |
| US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
| UY32562A (es) * | 2009-04-15 | 2010-11-30 | Astrazeneca Ab | Pirimidinas sustituidas por imidazol 724 |
| CA2756759C (en) | 2009-04-16 | 2017-11-07 | Joaquin Pastor Fernandez | Imidazopyrazines for use as kinase inhibitors |
| BR112013020329A2 (pt) * | 2011-02-09 | 2016-08-02 | Hoffmann La Roche | compostos heterocíclicos como inibidores da pi3-quinase |
| CN104066735B (zh) * | 2012-01-10 | 2016-08-31 | 拜耳知识产权有限责任公司 | 作为akt激酶抑制剂的取代的咪唑并吡嗪 |
| PT2914296T (pt) * | 2012-11-01 | 2018-10-30 | Infinity Pharmaceuticals Inc | Tratamento de cancros utilizando moduladores de isoformas de pi3-quinase |
| DK3003309T3 (da) | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Behandling af cancer med PI3-kinase-isoform modulatorer |
| WO2015058084A1 (en) * | 2013-10-18 | 2015-04-23 | Medivation Technologies, Inc. | Heterocyclic compounds and methods of use |
| HRP20211813T1 (hr) | 2014-08-11 | 2022-03-04 | Acerta Pharma B.V. | Terapeutske kombinacije inhibitora btk i inhibitora bcl-2 |
| AR102220A1 (es) * | 2015-10-08 | 2017-02-15 | Incyte Corp | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 |
| EA037361B1 (ru) * | 2016-06-16 | 2021-03-18 | Янссен Фармацевтика Нв | Производные бициклического пиридина, пиразина и пиримидина в качестве ингибиторов pi3k бета |
| US11136323B2 (en) * | 2016-12-07 | 2021-10-05 | Beigene, Ltd. | Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors |
| JP7128264B2 (ja) | 2017-09-08 | 2022-08-30 | ベイジーン リミテッド | ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体 |
-
2018
- 2018-09-07 JP JP2020513700A patent/JP7128264B2/ja active Active
- 2018-09-07 CN CN202010273331.8A patent/CN111704615B/zh active Active
- 2018-09-07 WO PCT/CN2018/104559 patent/WO2019047915A1/en unknown
- 2018-09-07 HU HUE18853233A patent/HUE061898T2/hu unknown
- 2018-09-07 KR KR1020207007386A patent/KR20200052297A/ko not_active Application Discontinuation
- 2018-09-07 TW TW111147323A patent/TW202336010A/zh unknown
- 2018-09-07 IL IL272988A patent/IL272988B/en unknown
- 2018-09-07 BR BR112020004500-4A patent/BR112020004500A2/pt unknown
- 2018-09-07 FI FIEP18853233.7T patent/FI3679042T3/fi active
- 2018-09-07 CN CN201880057835.7A patent/CN111051312A/zh active Pending
- 2018-09-07 NZ NZ761680A patent/NZ761680A/en unknown
- 2018-09-07 TW TW107131522A patent/TWI817956B/zh active
- 2018-09-07 US US16/643,040 patent/US11220506B2/en active Active
- 2018-09-07 SG SG11202001286SA patent/SG11202001286SA/en unknown
- 2018-09-07 PT PT188532337T patent/PT3679042T/pt unknown
- 2018-09-07 PL PL18853233.7T patent/PL3679042T3/pl unknown
- 2018-09-07 EP EP18853233.7A patent/EP3679042B1/en active Active
- 2018-09-07 AU AU2018328569A patent/AU2018328569B2/en active Active
- 2018-09-07 ES ES18853233T patent/ES2944658T3/es active Active
- 2018-09-07 MX MX2020002630A patent/MX2020002630A/es unknown
- 2018-09-07 DK DK18853233.7T patent/DK3679042T3/da active
- 2018-09-07 CA CA3072842A patent/CA3072842A1/en active Pending
- 2018-09-07 EP EP23152036.2A patent/EP4219502A1/en active Pending
-
2020
- 2020-02-11 ZA ZA2020/00875A patent/ZA202000875B/en unknown
-
2021
- 2021-11-23 US US17/533,442 patent/US11905294B2/en active Active
-
2023
- 2023-10-25 AU AU2023254925A patent/AU2023254925A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277576A (en) | Mutated pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | |
| HK1258157A1 (zh) | 作為jak抑制劑的吡唑並[1，5-a]吡嗪-4-基衍生物 | |
| IL265918A (en) | Pyrazolo [1,5– A] compounds Pyridine is converted as RET kinase inhibitors | |
| HK1258905A1 (zh) | 作為ret激酶抑制劑的取代的吡唑並[1，5-a]吡啶化合物 | |
| IL254224A0 (en) | 7-substituted 5-alkyl-[4,2,1]triazolo[5,1-a]pyrimidine derivatives as pde2 inhibitors | |
| IL266305B (en) | History of [4,2,1]triazolo[5,1-a]pyrimidine as pde2 inhibitors | |
| IL247947B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrazine compounds and 8,7,6,5-tetrahydro-h4-pyrazolo[5,1-a][4,1]diazepine compounds as ros1 inhibitors | |
| IL290419B (en) | Imidazo[a-1,5]pyrazine derivatives as inhibitors of pi3k delta | |
| IL272988A (en) | Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors | |
| IL247948B (en) | 7,6,5,4-tetrahydro-pyrazolo[5,1-a]pyrimidine derivatives and 3,2-dihydro-h1-imidazo[2,1-b]pyrazole derivatives as ros1 inhibitors | |
| IL262673A (en) | Pyrazolo[1,5-a]pyrimidine compound |